Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00664027 · ClinicalTrials.gov registry record · Phase 2
Phase IIa Trial to Determine the Effects of Bardoxolone Methyl on Renal Function in Patients With Diabetic Nephropathy
A Phase 2 study, sponsored by Biogen.
- Completed
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
NCT00664027 is a Phase 2 study that has completed, run by Biogen. The registered enrollment target is 80 participants.
The verdict
NCT00664027, a Phase 2 study, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
Study Summary
To determine the effects of three different doses of bardoxolone methyl administered orally on the kidney function (glomular filtration rate) in patients with diabetic nephropathy.
Interventions
- DRUG RTA 402 (Bardoxolone Methyl)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2008-04-30 |
| Est. Completion | 2009-05-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00664027
The ClinicalTrials.gov registry entry for NCT00664027 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RTA 402 (Bardoxolone Methyl) is the first listed.
NCT00664027 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00664027 about?
NCT00664027 is a clinical study titled "Phase IIa Trial to Determine the Effects of Bardoxolone Methyl on Renal Function in Patients With Diabetic Nephropathy". To determine the effects of three different doses of bardoxolone methyl administered orally on the kidney function (glomular filtration rate) in patients with diabetic nephropathy.
What is the current status of trial NCT00664027?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2008-04-30. Estimated completion is 2009-05-31.
What interventions are being tested in trial NCT00664027?
The interventions under investigation include: RTA 402 (Bardoxolone Methyl) (DRUG).
Who is sponsoring clinical trial NCT00664027?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.